The Turning Points That Defined Leen Kawas’ Career
- bb
- 0
- Posted on
Every career has its inflection points—the moments that test conviction, redefine purpose, and shape legacy. For Leen Kawas, those turning points chart a journey from scientist to CEO, from entrepreneur to investor, and from visionary founder to architect of opportunity for others. Her story is one of both persistence and reinvention, tracing how a biochemist from Jordan became one of the most influential women in biotechnology.
The first turning point came long before the boardrooms and IPOs: in the lab. Kawas’s fascination with biochemistry began during her university studies, where she saw science not as abstraction but as a language for healing. Her early research focused on neurodegenerative diseases—conditions that strip away memory, identity, and independence. This emotional connection to purpose became a guiding thread throughout her career. “For me, science was never just about discovery,” she has said in interviews. “It was about restoring what people lose.”
That sense of mission led her to Washington State University, where her doctoral work explored regenerative compounds that could potentially reverse neural damage. It was there that her second major turning point occurred: the realization that translational science—the bridge from discovery to therapy—was where she could make the greatest impact. Rather than remain in academia, Leen Kawas chose to bring her research to the market, founding Athira Pharma in 2011.
Athira represented both risk and resolve. She stepped into a role few scientists dared to attempt: transforming a molecule into a business. Over the next decade, she navigated the company from concept to clinical trials, raising over $400 million and leading one of the most successful biotech IPOs of 2020. Her tenure marked her as one of only 22 female founders in the United States to take a company public—a milestone that reflected not only scientific achievement but leadership endurance.
The third turning point was more personal—a moment of reflection that reshaped how Leen Kawas thought about legacy. After stepping away from Athira, she faced the difficult task of redefining her professional identity outside the company she built. That experience, while challenging, catalyzed her next evolution. “Resilience is learned in the quiet after disruption,” she has noted. “It’s when you discover what really drives you.”
From that reflection emerged Propel Bio Partners, the biotech-focused venture fund she co-founded to support the next generation of life science innovators. For Kawas, this wasn’t just an investment vehicle—it was a philosophy of inclusion. She saw how many promising founders, especially women and minority scientists, struggled to access capital and mentorship. Propel was designed to change that dynamic, providing funding, infrastructure, and strategic guidance to help others navigate the same path she once walked.
Her latest chapter—as CEO of EIT Pharma and board member of Inherent Biosciences—marks the culmination of these lessons. Having led companies from preclinical discovery to the public markets, she now focuses on accelerating therapies that can meaningfully transform lives. Yet she approaches leadership with a broader lens. It’s no longer only about advancing a single molecule or company—it’s about shaping an ecosystem where innovation thrives sustainably and ethically.
Each phase of her career reflects a recurring theme: movement toward greater impact. From bench science to boardrooms, Kawas has continually expanded her sphere of influence without losing sight of her original motivation—to bridge the distance between possibility and patient. Her leadership blends the precision of a scientist with the empathy of a healer, making her a rare figure in biotech: one who speaks the languages of both molecules and markets fluently.
The turning points that define Leen Kawas’s journey are not marked by awards or headlines, but by the decisions that required courage—the choice to leave the lab, to lead under pressure, to begin again. Through them, she has built more than a career; she has built a framework for what modern scientific leadership can look like: visionary yet disciplined, ambitious yet humane.
In an industry defined by volatility and discovery, Kawas’s story reminds us that transformation doesn’t happen in a single breakthrough moment—it happens in every decision to keep building after one.
Learn more about Kawas in her bio on eitpharma.com.